Chandigarh Herald

Angelman Syndrome Pipeline Analysis, Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies, and Treatment Algorithm

 Breaking News
  • No posts were found

Angelman Syndrome Pipeline Analysis, Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies, and Treatment Algorithm

September 01
19:01 2021
Angelman Syndrome Pipeline Analysis, Clinical and Non-Clinical Studies, Therapeutic Assessment, Emerging Therapies,  and Treatment Algorithm
Delveinsight Business Research LLP
Angelman Syndrome Pipeline Insight, 2021″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Angelman Syndrome Market.

The Angelman Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the Angelman Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angelman Syndrome collaborations, mergers, acquisition, funding, designations, and other product-related details.

Angelman Syndrome Pipeline Analysis

The pipeline for Angelman Syndrome is not robust. To counter the current unmet needs of the market and to provide better treatment options for Angelman syndrome, companies across the globe are diligently involved in developing therapies. With the ongoing research studies at both the industry and university levels, the future of Angelman syndrome treatment seems promising. Research for future treatment options is focused on gene therapies, topoisomerase inhibitors, minocycline, cannabidiols, and PP2A inhibitors (LB-100).

 Some of the key companies in the Angelman Syndrome market include:

  • StrideBio

  • Ovid Therapeutics

  • PTC Therapeutics

  • GeneTx Biotherapeutics

  • Sarepta Therapeutics

And others.

Angelman Syndrome Therapies covered in the report includes:

  • Gaboxadol (OV101)

  • GTX-101 and GTX-102

  • GT-AS/AGIL-AS

 And many others.

Request for sample pages to discover more about the emerging therapies and key companies operating in the therapeutics segment: https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight

Angelman Syndrome Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Angelman Syndrome with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Angelman Syndrome Treatment.

  • Angelman Syndrome key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Angelman Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Angelman Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Request for Sample @ Angelman Syndrome Novel Therapies And Emerging Technologies 

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Angelman Syndrome.    

  • In the coming years, the Angelman Syndrome market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

  • The companies and academics are working to assess challenges and seek opportunities that could influence Angelman Syndrome Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  • A detailed portfolio of major pharma players who are involved in fueling the Angelman Syndrome treatment market. Several potential therapies for Angelman Syndrome are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Angelman Syndrome market size in the coming years.  

  • Our in-depth analysis of the Angelman Syndrome pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. Angelman Syndrome 

3. Angelman Syndrome Current Treatment Patterns

4. Angelman Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Angelman Syndrome Late Stage Products (Phase-III)

7. Angelman Syndrome Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Angelman Syndrome Discontinued Products

13. Angelman Syndrome Product Profiles

14. Angelman Syndrome Key Companies

15. Angelman Syndrome Key Products

16. Dormant and Discontinued Products

17. Angelman Syndrome Unmet Needs

18. Angelman Syndrome Future Perspectives

19. Angelman Syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report: https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight

Latest Reports By DelveInsight

Angelman Syndrome Market Insights

DelveInsight’s ‘Angelman Syndrome Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Angelman Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Trending Healthcare Blogs 

Medical Drones in Healthcare Delivery System

To utilize the application of drones, today, several startups are exploring the potential of drones in the healthcare segment to safely transport medical material in remote, hard-to-reach geographies, and congested urban areas. However, despite several benefits, social acceptance and the lack of appropriate drone regulation is the key challenge in the widespread use. Currently, the leading players in the drone delivery segment include Zipline, Swoop Aero, WINGCOPTER, Matternet, Wing, and many others. Looking at the market potential many other players are expected to enter the segment in the near future. Read more: Drones in Healthcare Sector

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles